ZYME - Zymeworks Inc.About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $30.18 | Open | $30.37 |
| Volume | 234.3K | Market Cap | 1.393B |
| Yield | Last Dividend |
| Insider Selling: Zymeworks Inc. (NYSE:ZY... | 03/21/21 |
| Zymeworks Inc. (NYSE:ZYME) insider Kathryn O???driscoll sold 786 shares of the firm???s stock in a transaction dated Monday, March 15th. The shares we... | |
| Zymeworks Announces Five Presentations a... | 03/10/21 |
| Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of | |
| H.C. Wainwright Stick to Their Buy Ratin... | 02/25/21 |
| H.C. Wainwright Stick to Their Buy Rating for Zymeworks Inc | |
| Zymeworks Reports 2020 Year-End Financia... | 02/24/21 |
| VANCOUVER, Canada--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics... | |
| Zymeworks to Participate in Upcoming Inv... | 02/10/21 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Expands Commercial Team and Cr... | 02/09/21 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Canaccord Genuity Stick to Their Buy Rat... | 01/29/21 |
| Canaccord Genuity Stick to Their Buy Rating for Zymeworks Inc | |
| The Daily Biotech Pulse: Decision Day Fo... | 01/28/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 27) Abb... | |
| 2 Biotech Stocks Wells Fargo Says Are Re... | 01/25/21 |
| The biotech sector has started the year with a bang. The industry benchmark, iShares NASDAQ Biotechnology ETF (IBB), is up ~11% so far in January -- f... | |
| Zanidatamab Data Highlight Durable Antit... | 01/15/21 |
| Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated cl | |
| Raymond James Stick to Their Buy Rating ... | 01/13/21 |
| Raymond James Stick to Their Buy Rating for Zymeworks Inc | |
| Leerink Partners Stick to Their Buy Rati... | 01/12/21 |
| Leerink Partners Stick to Their Buy Rating for Zymeworks Inc | |
| Zymeworks Highlights 2020 Achievements a... | 01/11/21 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Announces Expansion of Zanidat... | 12/01/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biothe... | |
| Zymeworks Receives Orphan Drug Designati... | 11/19/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biothe... | |
| Zymeworks and ALX Oncology Announce Clin... | 11/16/20 |
| Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NA | |
| Raymond James Stick to Their Buy Rating ... | 11/04/20 |
| Raymond James Stick to Their Buy Rating for Zymeworks Inc | |
| Zymeworks Reports 2020 Third Quarter Fin... | 11/03/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks , Will stock surge before Earn... | 11/03/20 |
| Zymeworks announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Zymeworks Inc. (NYSE:ZYME) Sees Signific... | 10/21/20 |
| Zymeworks Inc. (NYSE:ZYME) was the target of a significant decrease in short interest in the month of September. As of September 30th, there was short... | |
| Zymeworks Inc. (NYSE:ZYME) Short Interes... | 10/21/20 |
| Zymeworks Inc. (NYSE:ZYME) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest ... | |
| Zymeworks Target of Unusually Large Opti... | 10/21/20 |
| Zymeworks Inc. (NYSE:ZYME) was the recipient of unusually large options trading on Monday. Traders acquired 1,032 put options on the stock. This repre... | |
| Zymeworks Sees Unusually High Options Vo... | 10/20/20 |
| Zymeworks Inc. (NYSE:ZYME) was the recipient of unusually large options trading activity on Monday. Stock investors purchased 1,032 put options on the... | |
| Zymeworks Inc. (NYSE:ZYME) Sees Large De... | 10/20/20 |
| Zymeworks Inc. (NYSE:ZYME) saw a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,98... | |
| Checkpoint Therapeutics, Nano-X Imaging ... | 09/11/20 |
| Gainers: Checkpoint Therapeutics (NASDAQ:CKPT) +29%, Nano-X Imaging (NASDAQ:NNOX) +21%, Biofrontera AG (NASDAQ:BFRA) +20%, Zymeworks (NYSE:ZYME) +14%,... | |
| Zymeworks to Present at Upcoming Investo... | 09/03/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Reports 2020 Second Quarter Fi... | 08/05/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Corporate Update Webcast and C... | 07/08/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bioth... | |
| Zymeworks Announces New Multispecific An... | 07/08/20 |
| Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longti | |
| Strong Buy rating | 03/31/21 |
| Credit Suisse initiates coverage with Outperform rating and announces Price Target of $55.00 | |
| Buy rating | 02/25/21 |
| SVB Leerink downgrades from Outperform to Market Perform rating and lowers Price Target from $50.00 to $41.00 | |
| Buy rating | 02/08/21 |
| and announces Price Target of $57.00 | |
| Hold rating | 01/25/21 |
| Citigroup downgrades from Buy to Neutral rating and raises Price Target from $50.00 to $53.00 | |
| rating | 01/19/21 |
| Raymond James maintains Strong Buy rating and raises Price Target from $60.00 to $74.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
